NKTR · XBRL financial data
Nektar Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NKTR's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 153 | 102 | 92 | 90 | 98 | 55 |
| Cost of goods and services sold | 19 | 25 | 22 | 34 | 31 | 0 |
| Research and development | 409 | 400 | 218 | 114 | 121 | 117 |
| General and administrative | 105 | 123 | 92 | 77 | 77 | 69 |
| Operating income (loss) | (425) | (446) | (376) | (264) | (105) | (140) |
| Interest income | — | 3 | 7 | 19 | 15 | 10 |
| Interest expense | 7 | 0 | 0 | — | — | — |
| Other income (expense) | 18 | 3 | 7 | (6) | (0) | 0 |
| Income tax expense (benefit) | 0 | 1 | 3 | (0) | (0) | (0) |
| Net income (loss) | (444) | (524) | (368) | (276) | (119) | (164) |
| Earnings per share, basic‡ USD per share | (7,622.41) | (8,755.06) | (6,030.58) | (4,438.75) | (1,775.50) | (139.00) |
| Earnings per share, diluted‡ USD per share | (7,622.41) | (8,755.06) | (6,030.58) | (4,438.75) | (1,775.50) | (139.00) |
| Weighted average shares, basic‡ millions of shares | 0 | 0 | 0 | 0 | 0 | 1 |
| Weighted average shares, diluted‡ millions of shares | 0 | 0 | 0 | 0 | 0 | 1 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.999925000374997 stock split (December 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2026); filings made before it reported them unadjusted.
- † Share count changed about 33x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (NKTR's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 199 | 25 | 88 | 35 | 44 | 15 |
| Marketable securities | 863 | 709 | 417 | 268 | 211 | 231 |
| Marketable securities, non-current | 137 | 65 | 0 | 26 | 14 | 0 |
| Accounts receivable | 39 | 22 | 6 | 1 | 0 | — |
| Inventory | 15 | 16 | 19 | 16 | 0 | 0 |
| Total current assets | 1,138 | 796 | 546 | 331 | 261 | 266 |
| Property and equipment, net | 60 | 61 | 32 | 19 | 3 | 2 |
| Right-of-use asset | 126 | 117 | 53 | 18 | 8 | 3 |
| Goodwill | 77 | 77 | 77 | 0 | — | — |
| Total assets | 1,539 | 1,117 | 711 | 398 | 304 | 280 |
| Accounts payable | 22 | 10 | 13 | 10 | 12 | 11 |
| Accrued liabilities | — | — | 37 | 22 | 30 | 22 |
| Total current liabilities | 116 | 85 | 68 | 51 | 61 | 54 |
| Lease liability, non-current | 136 | 126 | 113 | 99 | 83 | 65 |
| Total liabilities | 461 | 438 | 344 | 267 | 243 | 191 |
| Accumulated deficit | (2,309) | (2,833) | (3,201) | (3,477) | (3,596) | (3,760) |
| Total stockholders' equity | 1,077 | 680 | 367 | 131 | 61 | 90 |
| Total liabilities and equity | 1,539 | 1,117 | 711 | 398 | 304 | 280 |
| Common shares outstanding (cover page)‡ millions of shares | 0 | 0 | 0 | 0 | 0 | 2 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.999925000374997 stock split (December 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.285714285714285 stock split (March 2026); filings made before it reported them unadjusted.
- † Share count changed about 33x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (NKTR's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (444) | (524) | (368) | (276) | (119) | (164) |
| Depreciation and amortization | 13 | 13 | 12 | 7 | 4 | — |
| Net cash from operating activities | (313) | (413) | (304) | (193) | (176) | (209) |
| Purchases of property and equipment | 7 | 15 | 6 | 1 | 1 | 0 |
| Net cash from investing activities | 496 | 203 | 366 | 140 | 143 | (1) |
| Share repurchases | — | — | — | 0 | 3 | 0 |
| Net cash from financing activities | (80) | 36 | 2 | 0 | 42 | 181 |
| Net change in cash | 103 | (174) | 63 | (53) | 9 | (29) |
- † Share count changed about 33x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Nektar Therapeutics | 39 | 10 | (76)* | 34.1M | 9.0 quarters | 10-QJun 30, 2026 |
| Aura Biosciences | 68 | not reported | (33)* | 103.7M | 2.1 quarters | 10-QJun 30, 2026 |
| Prothena Corp Public | 288 | 1 | (25)* | 51.3M | 11.5 quarters | 10-QJun 30, 2026 |
| Altimmune | 63 | not reported | (24)* | 194.5M | 13.5 quarters | 10-QJun 30, 2026 |
| Usana Health Sciences | 169 | 223 | 23* | 18.5M | — | 10-QJul 4, 2026 |
| Rigel Pharmaceuticals | 61 | 79 | 31* | 18.7M | — | 10-QJun 30, 2026 |
| Siga Technologies | 118 | 41 | 15* | 71.8M | — | 10-QJun 30, 2026 |
| Amarin | 157 | 40 | 9.2* | not reported | — | 10-QSep 30, 2026 |
| Northwest Biotherapeutics | 0.6 | 0.8 | (7.2)* | 1.7B | 0.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.